Neurodegenerative drug discovery has always been challenging, with surging costs, failed developments, modeling limitations, and misunderstood underlying disease mechanisms blocking the way. According to the American Society for Biochemistry and Molecular Biology, 90% of clinical drug development fails due to a lack of clinical efficacy, one of the top reasons for 40%-50% failures. Such a high rate of failure amplifies the need for more robust drug development infrastructures to address the situation and ensure efficient drug discovery.
This need inspired the birth of NEURO-SYS, founded with a blend of professional expertise and personal experience. With over 200 studies in 2025, 80% of bespoke models, 10,700 square feet of labs, 40% of PhDs, and 80+ posters and publications as its strengths, the firm has been revolutionizing drug development and neuroscience research since its establishment in 2013.
While integrating innovation into clinical trials, NEURO-SYS attains excellence in developing drugs to treat neurological diseases. Proudly acquiring the title of one of the ‘Innovators of the Year 2026’ by The CEO Views, the firm stands as a testament to excellence, innovation, and technological advancement in the realm of drug discovery.
An Establishment Rooted in Challenges
In the early stage of this firm’s establishment, NEURO-SYS’s Co-founder and CSO, Noelle Callizot, experienced firsthand the challenges of drug development when a promising compound failed. Motivated by this setback, NEURO-SYS was created to bridge the gap between preclinical discovery and finding a CRO that could reliably meet timelines while supporting complex downstream preclinical work.
It is a globally recognized, neuroscience-focused CRO that partners with biotech and pharmaceutical companies to deliver high-quality preclinical studies supporting therapeutic development in neurodegenerative diseases, rare neurological disorders, and peripheral neuropathies.
This enabled the company to scale while maintaining quality and service levels.
Additionally, NEURO-SYS has continually evolved its study paradigms and operational practices to remain aligned with changing regulatory expectations and market conditions. Expansion of the client base into the Asia-Pacific region has been another significant watershed in the firm’s journey. This step strengthened NEURO-SYS’s global footprint, enabling it to support neurodegenerative drug development programs across multiple geographies and diverse client needs.
Technology: A Tool to Win an Edge
NEURO-SYS leverages technology strategically by relying on a hands-on, science-driven approach rather than adopting tools at face value. The internal research and development team actively evaluates, pilots, and validates emerging technologies in-house before incorporating them into client studies. This approach allows NEURO-SYS to confidently offer validated technologies that enhance data quality and decision-making without introducing unnecessary risk into client programs.
Awards and Accolades
NEURO-SYS’s contribution to drug development and clinical research has been recognized with awards, marking its excellence and celebrating its success. The firm bagged a few awards for its unprecedented contribution to the field of medicine, which include-
- Best Neurodegenerative Disease CRO 2024 by Global Health Pharma
- CNS/PNS CRO of the Year 2023 by Global Health Pharma
- World’s Best CRO by Corporate Live Wire in 2021
- Top 10 CRO for 2021 by Pharma Tech Outlook
Future Endeavors
The next step for NEURO-SYS is continued, science-driven growth. Keeping science at the forefront of its plans, the firm aims to keep expanding its capabilities and support clients with proven and translational data, and advance neurodegenerative drug development in ways that ultimately benefit patients.
Making a Difference
Talking about the firm’s contribution to the drug development, discovery, and action research in the CNS (Central Nervous System) and PNS (Peripheral Nervous System) fields, CEO Yann Jaudouin mentioned, “NEURO-SYS contributes to CNS and PNS drug discovery and development by generating high-quality, translationally relevant preclinical models that de-risk programs and accelerate data-driven decision making.”
During early discovery, it supports the identification and prioritization of lead candidates using validated pharmacological tools and target-engagement strategies. As programs advance, NEURO-SYS’s models and custom study designs support the mechanism of action validation, dose optimization, and go/no-go decisions, while aligning endpoints with clinical relevance. Across both CNS and PNS indications, the company focuses on high-quality data, timelines, and partnerships.
Innovation in Drug Development and Research
Innovation in NEURO-SYS means continuous integration of emerging technologies, maintaining deep engagement with the scientific community, and investing in internal R&D to expand its preclinical model portfolio. It offers a specialized, neuroscience-first suite of preclinical services designed to support CNS and PNS drug discovery and development with a high degree of translational relevance. Unlike large, generalist CROs, NEURO-SYS operates as a focused, agile partner, providing hands-on scientific collaboration while consistently delivering on the quality and timelines its clients rely on.
Watersheds Worth Mentioning
As NEURO-SYS evolved, it continued to add more feathers to the cap. The milestones it achieved reflect the company’s growth and flexibility in a dynamic biotech landscape. One of the key milestones was the expansion of its facilities to support increasing demand and a growing portfolio of preclinical studies.
“Through conference participation, grant-supported collaborations, and model development, we ensure our services evolve in step with the needs of our clients and the field.”
